Summary. The aim of this study was to evaluate the ability of high-resolution computerized tomography (HRCT) of the chest and chest x-rays (CXR) to determine ef®cacy of inhaled recombinant human DNase (rhDNase) in cystic ®brosis (CF) patients younger than 5 years of age. A randomized, double-blind, placebo-controlled pilot study of 12 patients with CF younger than 5 years of age, attending the University of Michigan Cystic Fibrosis Center (Ann Arbor, MI) was conducted. The changes in the HRCT and CXR score from baseline to day 100 of therapy were assessed using a previously validated scoring system.
INTRODUCTION
Respiratory disease in patients with cystic ®brosis is caused by the accumulation of purulent, infected sputum in the airways and leads to obstruction of the small airways, and a state of chronic low-grade infection. 1 Sputum in CF is rich in leukocyte-derived DNA that greatly contributes to abnormal viscoelasticity of the CF sputum.
2 CF patients younger than 5 years of age have signi®cant amounts of DNA in their airway. 3 Recombinant human DNase 1 (rhDNase), a copy of the native human enzyme responsible for hydrolyzing extracellular DNA, dramatically alters the viscoelastic properties of CF sputum in vitro. 4 Aerosol administration of rhDNase (Pulmozyme
1
, Genentech, Inc., South San Francisco CA) with a pneumatically driven hand-held nebulizer improves pulmonary function in CF patients. The improvement was noted within days of initiating therapy. 5, 6 In addition, long-term administration of rhDNase reduced the need for parenteral antibiotic treatment of respiratory tract infections and the rate of hospitalization. 7 Most ef®cacy studies have been done in CF patients older than 5 years of age because they can perform pulmonary function testing to evaluate objectively the ef®cacy of this drug. The safety of rhDNase has been studied in CF children younger than 5 years of age. 8 Patients younger than 5 years of age have been excluded from ef®cacy trials because of their inability to perform pulmonary function tests with predetermined standards. However, 17.6% of the CF patient population in the USA in 1997 were younger than 5 years of age; of these, 598 patients (16.2% of the total in that age group) were reported to be receiving rhDNase. 9 High-resolution computed tomography (HRCT) of the chest has been used to evaluate the progression and severity of lung disease in CF.
10±14 Several scoring systems for HRCT have been developed to evaluate lung disease in CF. 11, 12 Multiple studies have shown that CT scanning is more sensitive and speci®c than chest radiography. 11, 12, 14, 15 CT scanning can localize and qualitatively describe focal areas of parenchymal abnormality. 16 We designed a randomized, double-blind, placebocontrolled clinical trial to evaluate the ability of HRCT and chest x-rays (CXR) to detect lung changes after administering rhDNase in children younger than 5 years of age with CF.
PATIENTS AND METHODS
Patients with CF younger than 5 years of age and attending the University of Michigan CF Center were considered eligible for the study. We enrolled 12 patients (8 males and 4 females) with a mean age of 3.06 AE 1.49 years (mean AE SD), and a range of 1.10±4.99 years, all with a con®rmed diagnosis of CF by abnormal values of sweat chloride (Table 1) . To ensure that patients were clinically stable prior to enrollment, patients receiving antibiotics within 2 months prior to enrollment and who were hospitalized for a pulmonary exacerbation within 3 months prior to enrollment were excluded. No participants had received rhDNase or any investigational drug therapy within 6 months prior to enrollment. All patients had received standard care for cystic ®brosis. 17 Patients were assigned at random to one of the study groups.
Patients were randomly assigned to receive either 2.5 mg of rhDNase or placebo once a day for 100 days. The dose was based on the results of a previous study. 7 Both physicians and parents were blind with respect to the treated and placebo groups. Genentech, Inc. provided the rhDNase (Pulmozyme 1 ) and placebo used in the study. rhDNase was provided as a solution (1 mg/mL) in 2.5 mL of excipient (150 mM sodium chloride, 1.5 mM calcium chloride, pH 6.0). The placebo was excipient alone. The study drug was nebulized once a day using the ProNeb 1 compressor/nebulizer system (PARI Respiratory Equipment, Inc., Midlothian, VA). Vials were returned and counted at the end of the study as a measure of compliance. The study was reviewed and approved by the University of Michigan Institutional Review Board, and informed consent was obtained from all parents or guardians.
The patients were evaluated upon enrollment and at the end of the study. Blinding for the study was done in a random fashion, regardless of the number of pulmonary exacerbations or colonization status prior to enrollment. Anteroposterior and lateral CXR projections and HRCT were obtained on both occasions. A questionnaire was developed and used to assess the patients' general sense of well-being (with questions about activity level, appetite, and sleep pattern) and CF-related symptoms (with questions about frequency and nature of cough, wheezing, retraction, and shortness of breath). The parents completed a questionnaire upon enrollment and at the end of the study. The number of days of daycare or preschool missed because of CF related illnesses were recorded. Upon enrollment, a deep oropharyngeal culture was obtained to assess colonization status with Pseudomonas aeruginosa (Table 1 HRCT scan was done using 40 milliamperes, 1 sec scan time per slice, and 140 kV for each of ®ve evenly spaced 1-mm-thick slices through the lungs. The CT scanner was a HiSpeed Advantage 1 scanner (General Electric Medical Systems, Milwaukee, WI). Because of the speed of the scanner and the limited number of slices (®ve), HRCT was done without sedation. Based on the study of Mayo et al. 16 and phantom (plastic model simulating cross section of the lung) studies done on our scanner, 19 we estimated the peak dose within each slice to be 300±500 mrem and the average dose to the entire lung to be 50 mrem. Each slice was processed using a bone algorithm and photographed 4 on 1 on a 14 inch by 17 inch ®lm, using a window width of 1,000 Houns®eld units (HU) and a level of À600 HU.
The HRCT scans were scored by two pediatric radiologists (P.J.S. and K.A. Garver), using the modi®ed HRCT scoring system described by Santamaria et al., 20 modi®ed from Bhalla et al. 11 Both radiologists were blind to the patients' treatment assignment. HRCTs were read at random. The HRCT ®nal score of each patient was calculated on the basis of severity and extent of the morphologic changes, and represented the average score from two observers. The highest possible score was 30, which indicated severe lung disease.
The chest radiographs were scored independently and in a blinded manner by a pediatric radiologist (L.R.K.) and a pediatric pulmonologist (S.Z.N.) using the Bras®eld score, 21 and the scores were averaged. This scoring system has been used to evaluate the severity of CF lung disease. A score of 25 points indicates normal lungs. The score decreases with increasing severity of lung disease.
The CXR and HRCT images were presented in random, independent order for evaluation by two observers. To estimate the interobserver reliability in scoring CXR and HRCT images, the interobserver coef®cients of variation of either CXR or HRCT score were calculated using the formula:
Coef®cient of variation
Absolute mean difference Â 100 (expressed as a percentage)
Overall mean of scores where the``absolute mean difference'' is the mean of the absolute value in the differences in the scores of the two observers, and the``overall mean of scores'' is the mean of the scores of the two observers for all subjects included. Differences in means were tested for signi®-cance in assessing interobserver reliability, using a paired samples t-test. Correlation coef®cients were tested for signi®cance using a Pearson's product-momentum coef®cient.
Comparative analyses of the two groups in the clinical trial are presented as mean AE SD. Differences in means were tested in these cases, using a t-test for independent samples. This was a pilot study; no sample size calculation was performed. The number of subjects studied was arbitrarily chosen. All analyses were carried out in SPSS (Statistical Package for Social Science) (SPSS, Inc., Chicago, IL)
RESULTS
Twelve patients were enrolled and randomized to one of two treatment groups. Clinical characteristics of the two groups are presented in Table 1 . One patient in the rhDNase group used only two vials; the rest of the patients in the two groups used 89±100 vials. Most of the study population had mild respiratory disease as assessed by CXR score (10 patients scored !21, 1 patient scored 20, and 1 patient scored 18 Bras®eld units) and HRCT score (11 patients scored`5 and 1 patient scored 8.5). There was no difference in CXR score at baseline between the two groups. Table 2 represents a summary of HRCT scores ®ndings in the two study groups. The HRCT scans were free of respiratory motion artifact in 5 out of 6 patients older than 2.2 years, and in 1 out of 6 patients younger than 2.2 years. Motion artifact assessment was subjective. The two readers were able to read and score all HRCTs. Table 3 summarizes the means AE SD and ranges for CXR and HRCT scores for both study groups before and at the end of the study period.
The CXR scoring system had excellent interobserver reliability. The interobserver coef®cient of variation for the CXR score was 3.1%. The HRCT score had a higher interobserver coef®cient of variation (49.1%). That was due to the low scoring scale for HRCT scans (10 points maximum) vs. higher scoring scale for CXR (25 points), and the small number of subjects in this study. Mean CXR scores showed a trend towards a signi®cant statistical difference between the two observers (22.17 AE 0.61 vs. 21.50 AE 0.51 (mean AE SEM); P 0.09). There was no statistically signi®cant difference between the two observers for mean HRCT scores (2.00 AE 0.83 vs. 2.42 AE 0.66; P 0.38). The correlation coef®cients for CXR and HRCT scores between the two observers were 0.82 and 0.84, respectively, with both values being statistically signi®cant (P`0.001). There was no statistically signi®cant correlation between CXR and HRCT scores (r À0.4, P 0.15).
There was a signi®cant correlation between speci®c HRCT changes for bronchiectasis, peribronchial thickening, mucus plugging, and air trapping, and the total HRCT score (r 0.8, r 0.9, r 0.8, r 0.9 respectively, P`0.001 for all subscores). Acinar nodules/consolidation, thickening of intra-interlobular septae, and ground glass opacities were signi®cantly correlated to the total HRCT score, with P`0.05 and r 0.6 for all subscores. When the analysis was performed to relate the HRCT subscores to CXR score, only thickening of the intrainterlobular septae was signi®cantly correlated with the total CXR score (r À0.7, P`0.01).
We compared the effects of rhDNase treatment and the placebo group, using the CXR and HRCT scores. There was no signi®cant difference between either the CXR scores or the HRCT scores between the two groups at baseline. To compare the effects of the treatment on the two groups, a``gain score'' was calculated by subtracting the CXR and HRCT scores before treatment from the scores after treatment. When the change in HRCT scores over the treatment period was calculated, the difference in the mean change between the rhDNase and placebo groups was found to be signi®cant, with mean changes AE SE being À1.00 AE 0.53 and 0.58 AE 0.24 for the rhDNase and placebo groups, respectively (P 0.02). The difference in the mean change in CXR scores was not found to be statistically signi®cant, with mean AE SE being 0.67 AE 0.81 and À1.25 AE 0.97 for the rhDNase and placebo groups, respectively (P 0.16).
Parents of 4 of the 6 patients randomized to rhDNase recorded improvement in patients' physical activity, decreased cough, better sleep quality, and improved appetite. Parents of 4 of the 6 patients in the placebo group recorded lack of improvement while in the study. Parents of 2 of the 6 patients in each group were not sure if their children's clinical status changed during the study period. No signi®cant adverse effects were attributed to the administration of rhDNase.
DISCUSSION
In this preliminary, short-term study, we demonstrated the ef®cacy of aerosolized rhDNase in patients younger than 5 years of age with cystic ®brosis. Since standards have not been determined for pulmonary function testing in this age group, ®nding an alternative measure to evaluate the ef®cacy of rhDNase therapy is crucial. In this study we used CXR and HRCT scores as objective measures of clinical response in this young patient population. The administration of rhDNase led to subjective improvement as reported by the parents, including decreased cough, increased activity level, improved appetite, and improved sleep. There were none of the complications of using rhDNase (alteration in voice, pharyngitis, and laryngitis) seen in older patients. 7 The lack of adverse effects in our study population could re¯ect the small number of subjects and the short duration of the study. Wagener et al. 8 also did not observe adverse effects in this age group.
There was improvement in both the CXR and the HRCT scores as compared with baseline values in the rhDNase group (Figs. 1, 2) , while there was a worsening of both scores in the placebo group. The interobserver coef®cient of variation for CXR scores was excellent (3.1%). The higher variation in HRCT scores (49.1%) probably re¯ects the small range of the scoring system and the small number of patients. The current CT technology allowed us to perform the imaging procedure without sedation. This resulted in some motion artifact, especially in patients younger than 2.2 years. Performing the HRCT without sedation decreased the risk of the procedure, made it more acceptable to the parents, and decreased cost. The radiation dosage was less than conventional chest CT with our technique, as we acquired a limited number of slices (®ve) with a low mA and scan time. We estimated the integral dose to the thorax to be about a mean dose of 50 mRem, as based on Santamaria et al., 20 since the mAs in this study were one-tenth of the technique in that reference. The CT will give peaks and valleys of radiation to the thorax. The CXR in our institution gives a maximum skin external dose of 30±50 mrem. The integral dose of the two procedures should be nearly equal, even though the dose is delivered in a different manner by the two procedures.
There was signi®cant correlation between observers for both CXR and HRCT scores. This was consistent with the ®ndings of Santamaria et al. 20 There was no signi®-cant correlation between mean CXR and mean HRCT Fig. 1 . High-resolution CT scan of subject (age 4.5 years) who received rhDNase. A: HRCT at baseline shows bronchial wall thickening and inhomogeneity of aeration of lower lobe (ground-glass appearance). B: HRCT at end of study showed improvement in all categories listed above. A: HRCT at baseline shows RML interlobular septal thickening, peribronchial thickening, and atelectasis. B: HRCT at end of study shows improvement in all categories listed above. CXR for that patient (not shown) revealed no signi®cant changes in Bras®eld score between baseline and at completion of study.
scores. This is likely related to the high variability in HRCT scores. It could also relate to the difference in sensitivities of CXR and HRCT scores.
There were signi®cant correlations between most subscores and total HRCT scores, except for the number of bullae and collapse. These two subscores were not observed in this patient population with relatively mild CF disease. The subscores that correlated best with the total HRCT score were bronchiectasis, peribronchial thickening, mucus plugging, and air trapping.
Comparative analysis of the two patient groups revealed a statistically signi®cant difference in HRCT scores. The CXR score also showed improvement in the rhDNase group and worsening in the placebo group. However, these differences did not reach statistical signi®cance, probably due to the small sample size and the lower sensitivity of CXR vs. HRCT in the evaluation of early CF lung disease. These ®ndings would support the hypothesis that in mild CF, the use of HRCT is more sensitive and likelier to detect differences between study groups, and should be considered in evaluating different therapeutic interventions in this patient population. The use of HRCT as described here provides radiation doses similar to those of CXR. However, the information provided by HRCT is far superior and gives higher sensitivity than CXR.
This preliminary study suggests that aerosolized rhDNase is a safe and effective agent in CF patients younger than 5 years. A long-term study in a larger patient population would be of interest to further evaluate the bene®ts of this therapeutic modality to slow the progression of CF lung disease. HRCT can be used to objectively assess the severity of CF lung changes in preschool children who cannot perform pulmonary function tests. HRCT appears to be a more sensitive study than CXR in evaluating this patient population.
